ADAMTS13 and TTP
- 1 September 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 9 (5) , 389-394
- https://doi.org/10.1097/00062752-200209000-00001
Abstract
Thrombotic thrombocytopenic purpura (TTP) has been a mysterious and deadly disease that often could be treated effectively by plasma exchange, but without real understanding of the underlying pathophysiology. Recent advances now suggest that deficiency of a specific von Willebrand factor (VWF) cleaving protease promotes tissue injury in TTP. VWF multimers participate in the formation of platelet thrombi. Proteolytic cleavage of VWF multimers normally limits platelet thrombus growth, and failure to cleave VWF appears to encourage microvascular thrombosis. The VWF cleaving protease proves to be a new member of the ADAMTS family of metalloproteases, designated ADAMTS13. Autoantibodies that inhibit ADAMTS13 cause sporadic TTP, and mutations in the ADAMTS13 gene cause an autosomal recessive form of chronic relapsing TTP. Further studies of ADAMTS13 seem likely to change our approach to the diagnosis and treatment of TTP and other thrombotic microangiopathies.Keywords
This publication has 44 references indexed in Scilit:
- Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic PurpuraJournal of Biological Chemistry, 2001
- A Novel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly, the von Willebrand Factor--Cleaving Protease?The Journal of Biochemistry, 2001
- Purification of human von Willebrand factor–cleaving protease and its identification as a new member of the metalloproteinase familyBlood, 2001
- Partial amino acid sequence of purified von Willebrand factor–cleaving proteaseBlood, 2001
- Report on the workshop: Von Willebrand factor and thrombotic thrombocytopenic purpuraAmerican Journal of Hematology, 2001
- Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving proteaseBest Practice & Research Clinical Haematology, 2001
- How I treat patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndromeBlood, 2000
- Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1998
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982